Download PDF
Z Gastroenterol 2001; 39(8): 601-607
DOI: 10.1055/s-2001-16696
Übersichten
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Funktion des Immunsystems bei Leberzirrhose

Function of the immune system in liver cirrhosisM. J. Bahr, M. P. Manns
  • Abteilung Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover
Further Information

Publication History

Publication Date:
27 August 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bei Patienten mit Leberzirrhose lässt sich eine Reihe unterschiedlicher Fehlfunktionen im Immunsystem nachweisen. Diese betreffen sowohl die unspezifische Abwehr als auch die antigenspezifischen Reaktionen. Sehr gut untersucht und in seiner klinischen Bedeutung gut belegt ist die eingeschränkte Leistung des retikuloendothelialen Systems bei Leberzirrhose. Hier zeigt sich ein enger Zusammenhang zur Inzidenz bakterieller Infektionen und zur Prognose der Patienten. Andere Störungen wie die eingeschränkte Funktion neutrophiler Granulozyten sind wahrscheinlich für den klinischen Verlauf eher sekundär. Ob die gestörte Aktivierung der Natural-Killerzellen (NK-Zellen) und der lymphokinaktivierten Killerzellen (LAK-Zellen) eine Prädisposition für die Entwicklung eines hepatozellulären Karzinoms bei Leberzirrhose darstellt, müssen weitere Studien zeigen. Auffällig ist ein mäßig vermindertes Ansprechen auf Impfungen bei Leberzirrhose, was bei den meisten Impfstoffen aber durch eine Dosiserhöhung ausgeglichen werden kann.

Function of the immune system in liver cirrhosis

Malfunction of the immune system at different levels is typical for patients with liver cirrhosis. Both non-specific as well as antigen-specific functions may be compromised. The best studied and clinically most important problem is the diminished clearance capacity of the reticulo-endothelial system in liver cirrhosis. This transfers into a significantly higher rate of bacterial infections associated with a poorer prognosis in these patients. The clinical relevance of concomitant immune disorders like neutrophil dysfunction is less clear. An impaired activation of natural killer cells (NK) and lymphokine-actvated killer cells (LAK) may have a role in the development of hepatocellular carcinoma but additional studies are needed. Clinically important is a moderately reduced efficacy of standard immunization protocols, which can be overcome by an increased dose in most vaccines.

Schlüsselwörter

Immunsystem - Leberzirrhose - Infektionen - Makrophagen - RES - neutrophile Granulozyten - Natural-Killerzellen - Lymphozyten - Opsonine - Impfungen

Key words

Immune System - Liver Cirrhosis - Infections - Macrophages - RES - Neutrophile Granulocytes - Natural Killer Cells - Lymphocytes - Opsonines - Vaccination

Literatur

  • 1 Runyon B A. Bacterial infections in patients with cirrhosis.  J Hepatol. 1993;  18 271-272
    Google Scholar
  • 2 Beutler B A, Milsark I W, Cerami A. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo.  J Immunol. 1985;  135 3972-3977
    Google Scholar
  • 3 Castell J V, Geiger T, Gross V. et al . Plasma clearance, organ distribution and target cells of interleukin-6/hepatocytestimulating factor in the rat.  Eur J Biochem. 1988;  177 357-361
    Google Scholar
  • 4 Ferraiolo B L, Moore J A, Crase D. et al . Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.  Drug Metab Dispos. 1988;  16 270-275
    Google Scholar
  • 5 Klapproth J, Castell J, Geiger T, Andus T, Heinrich P C. Fate and biological action of human recombinant interleukin 1beta in the rat in vivo.  Eur J Immunol. 1989;  19 1485-1490
    Google Scholar
  • 6 Sonne O, Davidson O, Møller B K, Munck P etersen C. Cellular targets and receptors for interleukin-6: I. In vivo and in vitro uptake of IL-6 in liver and hepatocytes.  Eur J Clin Invest. 1990;  20 366-370
    Google Scholar
  • 7 Wisse E, Braet F, Luo D. et al .Sinusoidal liver cells. Oxford Textbook of Clinical Hepatology, 2nd edition (Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rodés J) Oxford; Oxford University Press 1999: 33-50
    Google Scholar
  • 8 van Bossuyt H, de Zanger R B, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts.  J Hepatol. 1988;  7 325-327
    Google Scholar
  • 9 Wisse E, Luo D, Vermijlen D. et al . On the function of pit cells, the liver-specific natural killer cells.  Semin Liver Dis. 1997;  17 265-286
    Google Scholar
  • 10 McCormick P A. The spleen, hypersplenism and other relationships between the liver and the spleen. Oxford Textbook of Clinical Hepatology, 2nd edition (Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rodés J) Oxford; Oxford University Press 1999: 787-795
    Google Scholar
  • 11 Shah S H, Hayes P C, Allan P L, Nicoll J, Finlayson N D. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis.  Am J Gastroenterol. 1996;  91 2580-2583
    Google Scholar
  • 12 Rozga J, Jeppsson B, Hagerstrand I, Bengmark S. Acute portal vein stenosis. An experimental study on portal circulation and hepatosplenic function.  Acta Chir Scand. 1985;  151 125-131
    Google Scholar
  • 13 el-Khishen M A, Henderson J M, Millikan W J Jr, Kutner M H, Warren W D. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension.  Surg Gynecol Obstet. 1985;  160 233-238
    Google Scholar
  • 14 Mbopi-Keou F X, Belec L, Lavril M. et al . Severe lymphopenia as a predictive marker for peritoneal infection in alcoholic cirrhosis.  Eur J Med. 1992;  1 317-318
    Google Scholar
  • 15 Gerok W, Rössle M, Schölmerich J. Leberzirrhose. Gerok W, Blum HE Hepatologie 2. Aufl München; Urban & Schwarzenberg 1995: 322-375
    Google Scholar
  • 16 Tomino S, Fujiwara H, Kagimoto T. et al . Decreased suppressor T cell activity in patients with hepatic cirrhosis.  Clin Exp Immunol. 1982;  48 625-632
    Google Scholar
  • 17 Holdstock G, Ershler  WB, Krawitt E L. Demonstration of non-specific B-cell stimulation in patients with cirrhosis.  Gut. 1982;  23 724-728
    Google Scholar
  • 18 Simon G, Gorbach S L. Intestinal flora in health and disease.  Gastroenterology. 1984;  86 174-193
    Google Scholar
  • 19 Lai D, Gorbach S L, Levitan R. Intestinal microflora in patients with alcoholic cirrhosis: Urea-splitting bacteria and neomycin resistance.  Gastroenterology. 1972;  62 275-279
    Google Scholar
  • 20 Martini G A, Phear E A, Ruebner E, Sherlock S. The bacterial content of the small intestine in normal and cirrhotic subjects: Relation to methionine toxicity.  Clin Sci. 1956;  16 35-51
    Google Scholar
  • 21 Morencos F C, de las H eras Castano G. et al . Small bowel bacterial overgrowth in patients with alcoholic cirrhosis.  Dig Dis Sci. 1995;  40 1252-1256
    Google Scholar
  • 22 Yang C Y, Chang C S, Chen G H. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests.  Scand J Gastroenterol. 1998;  33 867-871
    Google Scholar
  • 23 Llovet J M, Bartoli R, Planas R. et al . Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.  Gut. 1994;  35 1648-1652
    Google Scholar
  • 24 Runyon B A, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis.  J Hepatol. 1994;  21 792-796
    Google Scholar
  • 25 Rimola A, Navasa M. Infections in liver disease. Oxford Textbook of Clinical Hepatology, 2nd edition (Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rodés J) Oxford; Oxford University Press 1999: 1861-1874
    Google Scholar
  • 26 Garcia-Tsao G, Lee F Y, Barden G E, Cartun R, West A B. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites.  Gastroenterology. 1995;  108 1835-1841
    Google Scholar
  • 27 Sorell W T, Quigley E MM, Jin G, Johnson T J, Rikkers L F. Bacterial translocation in the portal-hypertensive rat: Studies in basal conditions and on exposure to hemorrhagic shock.  Gastroenterology. 1993;  104 1722-1726
    Google Scholar
  • 28 Campillo B, Pernet P, Bories P N. et al . Intestinal permeability in liver cirrhosis: relationship with severe septic complications.  Eur J Gastroenterol Hepatol. 1999;  11 755-759
    Google Scholar
  • 29 Caly W R, Strauss E. A prospective study of bacterial infections in patients with liver cirrhosis.  J Hepatol. 1993;  18 353-358
    Google Scholar
  • 30 Graudal N, Milman N, Kirkegaard E, Korner B, Thomsen A C. Bacteremia in cirrhosis of the liver.  Liver. 1986;  6 297-301
    Google Scholar
  • 31 Navasa M, Rimola A, Rodés J. Bacterial infections in liver disease.  Semin Liver Dis. 1997;  17 323-333
    Google Scholar
  • 32 Horan T C, White J W, Jarvis W R. et al . Nosocomial infection surveillance, 1984.  Morb Mortal Wkly Rep CDC Surveill Summ. 1986;  35 17SS-29SS
    Google Scholar
  • 33 EPINE W orking Group. Prevalence of hospital-acquired infection in Spain.  J Hosp Infect. 1992;  20 1-13
    Google Scholar
  • 34 Dinkel R H, Lebok U. A survey of nosocomial infections and their influence on hospital morality rates.  J Hosp Infect. 1994;  28 297-304
    Google Scholar
  • 35 Kuo C H, Changchien C S, Yang C Y, Sheen I S, Liaw Y F. Bacteremia in patients with cirrhosis of the liver.  Liver. 1991;  11 334-339
    Google Scholar
  • 36 Deschenes M, Villeneuve J P. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis.  Am J Gastroenterol. 1999;  94 2193-2197
    Google Scholar
  • 37 Runyon B A, Morrissey R L, Hoefs J C, Wyle F A. Opsonic activity of human ascitic fluid: A potentially important protective mechanism against spontaneous bacterial peritonitis.  Hepatology. 1985;  5 634-637
    Google Scholar
  • 38 Runyon B A. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis.  Gastroenterology. 1986;  91 1343-1346
    Google Scholar
  • 39 Runyon B A. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis.  Hepatology. 1988;  8 632-635
    Google Scholar
  • 40 Rimola A, Soto R, Bory F. et al . Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis.  Hepatology. 1984;  4 53-58
    Google Scholar
  • 41 Bolognesi M, Merkel C, Bianco S. et al . Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis.  Hepatology. 1994;  19 628-634
    Google Scholar
  • 42 Guarner C, Runyon B A. Macrophage function in cirrhosis and the risk of bacterial infection.  Hepatology. 1995;  22 367-369
    Google Scholar
  • 43 Gomez F, Ruiz P, Schreiber A D. Impaired function of macrophage Fc-gamma receptors and bacterial infection in alcoholic cirrhosis.  New Engl J Med. 1994;  331 1122-1128
    Google Scholar
  • 44 Fox R A, Dudley F J, Sherlock S. The serum concentration of the third component of complement beta-1C-beta-1A in liver disease.  Gut. 1971;  12 574-578
    Google Scholar
  • 45 Kourilsky O, LeRoy C, Peltier A P. Complement and liver cell function in 53 patients with liver disease.  Am J Med. 1973;  55 783-790
    Google Scholar
  • 46 Llach J, Rimola A, Navasa M. et al . Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration.  Hepatology. 1992;  16 724-727
    Google Scholar
  • 47 Tito L, Rimola A, Gines P. et al . Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors.  Hepatology. 1988;  8 27-31
    Google Scholar
  • 48 Altin M, Rajkovik I A, Hughes R D, Williams R. Neutrophil adherence in chronic liver disease and fulminant hepatic failure.  Gut. 1983;  24 746-750
    Google Scholar
  • 49 DeMeo A N, Andersen B R. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients.  New Engl J Med. 1972;  286 735-740
    Google Scholar
  • 50 Feliu E, Gougerot M A, Hakim J. et al . Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis.  Eur J Clin Invest. 1977;  7 571-577
    Google Scholar
  • 51 Maderazo E C, Ward P A, Quintiliani R. Defective regulation of chemotaxis in cirrhosis.  J Lab Clin Med. 1975;  85 621-360
    Google Scholar
  • 52 Rajkovic I A, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis.  Hepatology. 1986;  6 252-262
    Google Scholar
  • 53 Uehara M, Sato N. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.  Hepatology. 1994;  20 326-330
    Google Scholar
  • 54 Garcia-González M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis.  Gastroenterology. 1993;  105 527-531
    Google Scholar
  • 55 Yousif-Kadaru A GM, Rajkovik I A, Wyke R J, Williams R. Defects in serum attractant activity in different types of chronic liver disease.  Gut. 1984;  25 79-84
    Google Scholar
  • 56 Chuang W L, Liu H W, Chang W Y. et al . Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage.  Dig Dis Sci. 1991;  36 299-302
    Google Scholar
  • 57 Hirofuji H, Kakumu S, Fuji A. et al . Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: Evidence for a decreased lymphokine-induced activity of effector cells.  Clin Exp Immunol. 1987;  68 348-356
    Google Scholar
  • 58 Nakamura T, Morizane T, Watanabe T. et al . Decreased natural killer activity in patients with liver cirrhosis.  Int J Cancer. 1983;  32 573-575
    Google Scholar
  • 59 Ledesma F, Echevarria S, Casafont F, Lozano J L, Pons-Romero F. Natural killer cell activity in alcoholic cirrhosis: Influence of nutrition.  Eur J Clin Nutr. 1990;  44 733-740
    Google Scholar
  • 60 Nichigaki Y, Ohnishi H, Moriwaki H, Muto Y. Ursodeoxycolic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.  Dig Dis Sci. 1996;  41 1487-1493
    Google Scholar
  • 61 Shirachi M, Sata M, Miyajima I, Tanaka M, Tanikawa K. Liver-associated natural killer activity in cirrhotic rats.  Microbiol Immunol. 1998;  42 117-124
    Google Scholar
  • 62 Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma.  Hepatology. 1993;  18 315-319
    Google Scholar
  • 63 Hsu C CS, Leevy C M. Inhibition of PHA-stimulated lymphocyte transformation by plasma from patients with advanced alcoholic cirrhosis.  Clin Exp Immunol. 1971;  8 749-760
    Google Scholar
  • 64 Nouri-Aria K T, Alexander G JM, Portmann B C. et al . T and B cell function in alcoholic liver disease.  J Hepatol. 1986;  2 195-207
    Google Scholar
  • 65 Schirren C A, Jung M C, Zachoval R. et al . Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions.  Clin Exp Immunol. 1997;  108 144-150
    Google Scholar
  • 66 Franco D, Charra M, Jeambrun P. et al . Nutrition and immunity after peritoneovenous drainage of intractable ascites in cirrhotic patients.  Am J Surg. 1983;  146 652-657
    Google Scholar
  • 67 O’Keefe S J, El-Zayadi A R, Carraher T E, Davis M, Williams R. Malnutrition and immuno-incompetence in patients with liver disease.  Lancet. 1980;  ii 615-617
    Google Scholar
  • 68 Hirsch S, de la Marza M P, Gattas V. et al . Nutritional support in alcoholic cirrhotic patients improves host defenses.  J Am Coll Nutr. 1999;  18 434-441
    Google Scholar
  • 69 Keeffe E B, Iwarson S, McMahon B J. et al . Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease.  Hepatology. 1998;  27 881-886
    Google Scholar
  • 70 Keeffe E B, Krause D S. Hepatitis B vaccination of patients with chronic liver disease.  Liver Transpl Surg. 1998;  4 437-439
    Google Scholar
  • 71 McCashland T M, Preheim L C, Gentry-Nielsen M J. Pneumococcal vaccine response in cirrhosis and liver transplantation.  J Infect Dis. 2000;  181 757-760
    Google Scholar
  • 72 Villeneuve E, Vincelette J, Villeneuve J P. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation.  Can J Gastroenterol. 2000;  14 Suppl. B 59B-62B
    Google Scholar
  • 73 Wiedmann M, Liebert U G, Oesen U. et al . Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.  Hepatology. 2000;  31 230-234
    Google Scholar
  • 74 De Maria N, Idilman R, Colantoni A, Harig J M, Van Thiel D H. Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection.  Hepatology. 2000;  32 444-445
    Google Scholar
  • 75 Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list.  Liver Transpl. 2000;  6 440-442
    Google Scholar
  • 76 Horlander J C, Boyle N, Manam R. et al . Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation.  Am J Med Sci. 1999;  318 304-307
    Google Scholar

Prof. Dr. med. Michael P. Manns

Direktor der Abteilung Gastroenterologie und Hepatologie
Medizinische Hochschule Hannover

Carl-Neuberg-Straße 1

30623 Hannover

Email: Manns.michael@mh-hannover.de

      >